Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04179474 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
A Phase 1 study of Migraine, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT04179474 is a Phase 1 study of Migraine that has completed, run by Allergan. The registered enrollment target is 40 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04179474, a Phase 1 study of Migraine, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will evaluate the potential for a pharmacokinetic (PK) interaction and provide safety and tolerability information when ubrogepant and erenumab or ubrogepant and galcanezumab are co-administered.
Conditions Studied
Interventions
- DRUG Ubrogepant
- DRUG Galcanezumab
- DRUG Erenumab
Study Locations (2)
Missouri
- QPS - Springfield
Wisconsin
- Spaulding - West Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-09-26 |
| Est. Completion | 2019-12-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04179474
The ClinicalTrials.gov registry entry for NCT04179474 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (89% lower). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 3 interventions - of which Ubrogepant is the first listed.
NCT04179474 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Missouri, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04179474 about?
NCT04179474 is a clinical study titled "Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine". This study will evaluate the potential for a pharmacokinetic (PK) interaction and provide safety and tolerability information when ubrogepant and erenumab or ubrogepant and galcanezumab are co-administered.
What is the current status of trial NCT04179474?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2019-09-26. Estimated completion is 2019-12-23.
What conditions does trial NCT04179474 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT04179474?
The interventions under investigation include: Ubrogepant (DRUG), Galcanezumab (DRUG), Erenumab (DRUG).
Who is sponsoring clinical trial NCT04179474?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04179474 being conducted?
This trial has 2 study locations across Missouri, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
COMPLETED · Phase 1
-
Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults
COMPLETED · Phase 1
-
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
COMPLETED · Phase 1
-
A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants
COMPLETED · Phase 1
-
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
COMPLETED · Phase 1
-
Migraine Manager (R01)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.